55276
document
[ Effect of probucol on serum malondialdehyde and superoxide dismutase in patients with primary hypertension ] . OBJECTIVE To observe the therapeutic effect of probucol on serum malondialdehyde ( MDA ) and superoxide dismutase ( SOD ) in patients with primary hypertension . METHODS A randomized study was performed on 40 patients with hypertension . The patients were randomly assigned to the control ( levamlodipine besylate 2.5 mg/d plus benazepril 10 mg/d , n=20 ) or probucol group ( levamlodipine besylate 2.5 mg/d plus benazepril 10 mg/d plus probucol 500 mg/d , n=20 ) . An additional twenty healthy people were enrolled in the study ( normal group ) . All subjects were followed up for a period of four weeks . Lipids and hepatic/renal function were measured at baseline and after 4 weeks . The levels of serum MDA and SOD activity were assayed by chemical colorimetry , and other indices , including blood pressure , lipids and hepatic/renal function , were measured at baseline and after 4 weeks . RESULTS Compared to the normal group , the levels of MDA in all of the hypertension patient groups were higher , SOD was lower . The antihypertensive treatment decreased serum MDA levels but increased SOD content , and probucol treatment exaggerated these effects , with greater reduction of serum MDA levels and greater increase of SOD content . CONCLUSION The treatment with probucol can improve oxidative stress in hypertension patients , resulting in reduced serum MDA levels and improved SOD activity , thus contributing agreater antihypertensive effect .
55277
Intervention_Pharmacological
probucol
55278
Intervention_Pharmacological
probucol
55279
Intervention_Pharmacological
control ( levamlodipine besylate
55280
Intervention_Control
plus benazepril 10
55281
Intervention_Pharmacological
or probucol group ( levamlodipine besylate
55282
Intervention_Pharmacological
plus benazepril
55283
Intervention_Pharmacological
plus probucol
55284
Outcome_Physical
serum MDA and SOD
55285
Outcome_Physical
blood pressure , lipids and hepatic/renal function
55286
Outcome_Physical
levels of MDA
55287
Outcome_Physical
hypertension patient groups were higher , SOD was lower .
55288
Outcome_Physical
decreased serum MDA levels but increased SOD content
55289
Outcome_Physical
probucol treatment exaggerated these effects
55290
Outcome_Physical
greater reduction of serum MDA levels
55291
Outcome_Physical
greater increase of SOD content .
55292
Outcome_Physical
improve oxidative stress in hypertension patients
55293
Outcome_Physical
reduced serum MDA levels
55294
Outcome_Physical
improved SOD activity
55295
Participant_Condition
patients with primary hypertension .
55296
Participant_Condition
hypertension patients